ArticlePloS one2026
Artificial intelligence-driven identification and mechanistic exploration of synergistic anti-aging compounds from Dengzhan Shengmai formulation.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aging is a complex biological process involving multiple dysregulated pathways, and synergistic compound combinations offer distinct therapeutic advantages through multi-target and multi-pathway interactions. Traditional Chinese Medicine (TCM) formulations are inherently synergistic, yet systematically identifying their active anti-aging combinations remains a major challenge. Here, we developed DeepSMCA, a deep learning-based framework integrating molecular descriptors, ADMET parameters, and protein-protein interaction (PPI) network embeddings learned via a variational graph auto-encoder (VGAE), combined with a ResNetDNN classifier and the Bliss independence model, to identify synergistic combinations of anti-aging compound from the Dengzhan Shengmai (DZSM) formulation. Trained on 914 curated compounds, DeepSMCA achieved an area under the curve (AUC) of 0.9849 on the validation set, outperforming conventional machine learning and deep learning baselines, and interpretability analysis revealed that PPI network features contributed most (59.5%) to model predictions. Chemical profiling identified 30 constituents in DZSM, from which the three top-ranked synergistic combinations (Com1-3) were validated in D-galactose (D-Gal)-induced senescent PC12 cells. All three combinations enhanced cell viability, alleviated oxidative stress, attenuated intracellular reactive oxygen species accumulation, and decreased senescence-associated β-galactosidase-positive cells by up to 54.79%. Transcriptomic analysis showed that the combinations reversed 1,001-1,037 D-Gal-induced differentially expressed genes (DEGs), which were enriched in 18 shared aging-related pathways centered on longevity regulation, FoxO, p53, and autophagy signaling. Compound-target-aging-pathway network analysis further revealed complementary target engagement among constituents. This study establishes an interpretable, proof-of-concept computational-experimental pipeline for dissecting multi-component synergy in complex formulations, providing a generalizable strategy for anti-aging drug discovery from TCM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.